Exploring Updated Data for Large B-Cell Non-Hodgkin Lymphoma

August 05, 2020

Nilanjan Ghosh, MD, discusses the significance of the data from a pilot study of lisocabtagene maraleucel in patients ineligible for second-line transplant with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma.

Early Rituximab Intensification Generates No Differences in Outcomes as Treatment of DLBCL

August 04, 2020

Early rituximab intensification during treatment with R-CHOP demonstrated no difference in outcomes as treatment of patients with diffuse large B-cell lymphoma.

Lenalidomide/Rituximab Induction as Effective as Rituximab Plus Chemo in Follicular Lymphoma Subset

August 04, 2020

Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).

Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point

August 04, 2020

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL

August 01, 2020

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Axi-Cel Retains Its Benefit in a Real-World Setting in Large B-Cell Lymphomas

July 31, 2020

Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.

FDA Grants Orphan Designation to Cobomarsen for T-Cell Lymphomas

July 24, 2020

The FDA has granted an Orphan Drug designation to cobomarsen for the treatment of patients with T-cell lymphoma, according to an announcement from miRagen Therapeutics.

Camrelizumab Plus GVD Shows Synergistic Antitumor Activity in R/R Primary Mediastinal B-Cell Lymphoma

July 16, 2020

The combination of camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin demonstrated promising efficacy in patients with relapsed/refractory primary mediastinal B-cell lymphoma. The combination also had a manageable safety profile, according to findings from a phase 2 clinical trial.

FDA Grants Priority Review Pembrolizumab for Relapsed/Refractory Classical Hodgkin Lymphoma

July 09, 2020

The FDA granted Priority Review to pembrolizumab as treatment of patients with relapsed or refractory classic Hodgkin lymphoma.